Ventum Cap Mkts Cuts Earnings Estimates for Cresco Labs

Cresco Labs Inc. (OTCMKTS:CRLBF - Free Report) - Analysts at Ventum Cap Mkts cut their Q2 2025 earnings per share estimates for Cresco Labs in a research note issued on Monday, June 2nd. Ventum Cap Mkts analyst A. Semple now expects that the company will post earnings per share of ($0.04) for the quarter, down from their prior estimate of ($0.03). The consensus estimate for Cresco Labs' current full-year earnings is ($0.20) per share. Ventum Cap Mkts also issued estimates for Cresco Labs' Q3 2025 earnings at ($0.03) EPS, Q4 2025 earnings at ($0.03) EPS, FY2025 earnings at ($0.12) EPS and FY2026 earnings at ($0.07) EPS.

A number of other equities research analysts have also recently issued reports on CRLBF. Cormark raised Cresco Labs from a "hold" rating to a "moderate buy" rating in a research report on Monday, March 17th. Canaccord Genuity Group downgraded shares of Cresco Labs from a "strong-buy" rating to a "moderate buy" rating in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of "Buy".

Cresco Labs Stock Up 1.9%

Shares of OTCMKTS CRLBF traded up $0.01 during mid-day trading on Thursday, reaching $0.54. 718,874 shares of the company traded hands, compared to its average volume of 655,730. The company's fifty day moving average is $0.69 and its two-hundred day moving average is $0.84. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. Cresco Labs has a fifty-two week low of $0.49 and a fifty-two week high of $2.05. The stock has a market cap of $265.30 million, a PE ratio of -2.70 and a beta of 1.73.

Cresco Labs (OTCMKTS:CRLBF - Get Free Report) last posted its earnings results on Friday, May 30th. The company reported ($0.04) EPS for the quarter, missing the consensus estimate of ($0.03) by ($0.01). Cresco Labs had a negative return on equity of 16.52% and a negative net margin of 9.15%. The business had revenue of $165.76 million for the quarter, compared to analyst estimates of $164.37 million.

About Cresco Labs

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.